PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
4
Hangzhou Gaoxin Materials Technology
300478
5
Shijihengtong Technology
301428
US Stock MarketDetailed Quotes
GNTA Genenta Science
- 4.369
- +0.549+14.36%
Close Feb 14 16:00 ET
- 4.369
- 0.0000.00%
Post 20:01 ET
79.90MMarket Cap-8.50P/E (TTM)
4.369High3.940Low6.02KVolume3.940Open3.820Pre Close24.29KTurnover0.05%Turnover RatioLossP/E (Static)18.29MShares7.28052wk High4.53P/B49.04MFloat Cap2.20052wk Low--Dividend TTM11.23MShs Float13.130Historical High--Div YieldTTM11.22%Amplitude2.200Historical Low4.032Avg Price1Lot Size
Trending Stocks
Discussing
Major earnings are approaching! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1
Popular on moomoo
Feb 13 17:34
China's asset revaluation sparks debate: What are mooers buying?
Genenta Science Stock Forum
Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing
Thursday, 9th January at 6:00 am
MILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened its partnership with AGC Biologics, a global contract development and manufacturing organization (CDMO), by amending their Development and Master S...
Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer
Genenta Science (NASDAQ: GNTA) has received approval from AIFA for a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), expanding potential applications for its flagship product, Temferon™. This approval aligns with EMA standards. The company's ongoing TEM-GBM development program has completed a Phase 1 dose-ranging trial, confirming no dose-limiting toxicities across ...
it looks like this dip is an error. im not seeing the dip on my TD Ameritrade platform.
jumping in here..
No comment yet